IMCR in the 13F filings
Immunocore HLDGS PLC · CUSIP 45258D105
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 18 May 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 24
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 4 listed it in both
- Shares listed
- 17,813,332
- combined, among listed positions
- Reported value
- $537m
- combined, at the quarter end
Among the 91 comparable managers: 19 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +2,919,397.
Managers listing IMCR in Q1 2026
24 of 24 holders
Largest increases and reductions, by shares
Increases
- Two Sigma Investments LPexisting position · 1,021,265 shares now+661,972
- Point72 Asset Management LPexisting position · 1,102,271 shares now+598,120
- Millennium Management LLCexisting position · 1,237,403 shares now+325,806
- Fidelity (FMR LLC)existing position · 4,829,154 shares now+289,929
- Hudson Bay Capital Management LPexisting position · 633,174 shares now+249,616
Reductions
- T. Rowe Price Associates Incexisting position · 919,332 shares now-49,452
- Susquehanna International Group LLPexisting position · 8,622 shares now-26,566
- Voloridge Investment Management LLCexisting position · 19,492 shares now-8,672
- Citadel Advisors LLCexisting position · 230,399 shares now-3,869
- MFS Investment Managementexisting position · 407,373 shares now-31
New positions and exits
New (4)
Exited (3)
- Arrowstreet Capital LPwas $1.2m
- Schonfeld Strategic Advisors LLCwas $960k
- Tudor Investment Corpwas $772k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2021 | 2 | $5.9m | n.a. | n.a. |
| Q2 2021 | 1 | $5.4m | n.a. | n.a. |
| Q1 2022 | 1 | $12m | n.a. | n.a. |
| Q3 2022 | 2 | $32m | n.a. | n.a. |
| Q4 2022 | 4 | $181m | n.a. | n.a. |
| Q1 2023 | 2 | $203m | n.a. | n.a. |
| Q2 2023 | 4 | $416m | n.a. | n.a. |
| Q3 2023 | 5 | $353m | n.a. | n.a. |
| Q4 2023 | 4 | $511m | 3 | 1 |
| Q1 2024 | 6 | $609m | 4 | 1 |
| Q2 2024 | 4 | $248m | 3 | 1 |
| Q3 2024 | 4 | $259m | 4 | 0 |
| Q4 2024 | 4 | $232m | 2 | 2 |
| Q1 2025 | 5 | $238m | 3 | 2 |
| Q2 2025 | 5 | $193m | 1 | 4 |
| Q3 2025 | 4 | $205m | 1 | 3 |
| Q4 2025 | 5 | $214m | 16 | 8 |
| Q1 2026 | 4 | $182m | 19 | 8 |
| Q2 2026 | 4 | $248m | 15 | 10 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
IMCR and GILD →IMCR and AMGN →IMCR and ARGX →Choose a stock to compare with IMCR →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own IMCR, latest filings →Back to the 13F Explorer →